BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

389 related articles for article (PubMed ID: 29877267)

  • 1. The Analysis of Renal Infiltrating Cells in Acute Tubulointerstitial Nephritis Induced by Anti-PD-1 Antibodies: A Case Report and Review of the Literature.
    Tabei A; Watanabe M; Ikeuchi H; Nakasatomi M; Sakairi T; Kaneko Y; Maeshima A; Kaira K; Hirato J; Nojima Y; Hiromura K
    Intern Med; 2018 Nov; 57(21):3135-3139. PubMed ID: 29877267
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune checkpoint inhibitor (nivolumab)-associated kidney injury and the importance of recognizing concomitant medications known to cause acute tubulointerstitial nephritis: a case report.
    Koda R; Watanabe H; Tsuchida M; Iino N; Suzuki K; Hasegawa G; Imai N; Narita I
    BMC Nephrol; 2018 Feb; 19(1):48. PubMed ID: 29486725
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune checkpoint inhibitors associated granulomatous small vessel vasculitis accompanied with tubulointerstitial nephritis: a case report.
    Tominaga K; Takeuchi K; Takakuma S; Sakamoto E; Hatanaka S; Kajimoto Y; Toda E; Terasaki Y; Kunugi S; Terasaki M; Shimizu A
    BMC Nephrol; 2023 Mar; 24(1):48. PubMed ID: 36894873
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nivolumab-induced acute granulomatous tubulointerstitial nephritis in a patient with gastric cancer.
    Nakatani Y; Kawakami H; Ichikawa M; Yamamoto S; Otsuka Y; Mashiko A; Takashima Y; Ito A; Nakagawa K; Arima S
    Invest New Drugs; 2018 Aug; 36(4):726-731. PubMed ID: 29623482
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acute interstitial nephritis after sequential ipilumumab - nivolumab therapy of metastatic melanoma.
    Bottlaender L; Breton AL; de Laforcade L; Dijoud F; Thomas L; Dalle S
    J Immunother Cancer; 2017 Jul; 5(1):57. PubMed ID: 28716106
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acute tubulointerstitial nephritis and IgM deposits on glomerular capillary walls after immunotherapy with nivolumab for metastatic renal cell carcinoma.
    Irifuku T; Satoh A; Tani H; Mandai K; Masaki T
    CEN Case Rep; 2020 Feb; 9(1):48-54. PubMed ID: 31605271
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Successful Treatment of Non-small-cell Lung Cancer with Atezolizumab Following Tubulointerstitial Nephritis Due to Pembrolizumab.
    Taki T; Oda N; Fujioka Y; Mitani R; Tokura T; Takata I; Oshiro Y; Takigawa N
    Intern Med; 2020 Jul; 59(13):1639-1642. PubMed ID: 32269191
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnosis and Management of Immune Checkpoint Inhibitor-Associated Renal Toxicity: Illustrative Case and Review.
    Sise ME; Seethapathy H; Reynolds KL
    Oncologist; 2019 Jun; 24(6):735-742. PubMed ID: 30902916
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors.
    Cortazar FB; Marrone KA; Troxell ML; Ralto KM; Hoenig MP; Brahmer JR; Le DT; Lipson EJ; Glezerman IG; Wolchok J; Cornell LD; Feldman P; Stokes MB; Zapata SA; Hodi FS; Ott PA; Yamashita M; Leaf DE
    Kidney Int; 2016 Sep; 90(3):638-47. PubMed ID: 27282937
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Renal effects of immune checkpoint inhibitors.
    Izzedine H; Mateus C; Boutros C; Robert C; Rouvier P; Amoura Z; Mathian A
    Nephrol Dial Transplant; 2017 Jun; 32(6):936-942. PubMed ID: 28025384
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Critical renal adverse event induced by nivolumab therapy in a stage IV melanoma patient.
    Tanaka A; Ikinaga K; Kiyohara E; Tanemura A; Wataya-Kaneda M; Fujimura R; Mizui M; Isaka Y; Katayama I
    J Dermatol; 2017 Jun; 44(6):727-728. PubMed ID: 27461931
    [No Abstract]   [Full Text] [Related]  

  • 12. AKI in Patients Receiving Immune Checkpoint Inhibitors.
    Perazella MA; Sprangers B
    Clin J Am Soc Nephrol; 2019 Jul; 14(7):1077-1079. PubMed ID: 31048326
    [No Abstract]   [Full Text] [Related]  

  • 13. Thoracic and cutaneous sarcoid-like reaction associated with anti-PD-1 therapy: longitudinal monitoring of PD-1 and PD-L1 expression after stopping treatment.
    Paolini L; Poli C; Blanchard S; Urban T; Croué A; Rousselet MC; Le Roux S; Labarrière N; Jeannin P; Hureaux J
    J Immunother Cancer; 2018 Jun; 6(1):52. PubMed ID: 29898781
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review.
    Wanchoo R; Karam S; Uppal NN; Barta VS; Deray G; Devoe C; Launay-Vacher V; Jhaveri KD;
    Am J Nephrol; 2017; 45(2):160-169. PubMed ID: 28076863
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Histological diagnosis of immune checkpoint inhibitor induced acute renal injury in patients with metastatic melanoma: a retrospective case series report.
    Hultin S; Nahar K; Menzies AM; Long GV; Fernando SL; Atkinson V; Cebon J; Wong MG
    BMC Nephrol; 2020 Sep; 21(1):391. PubMed ID: 32894101
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Significance of M2 macrophage in tubulointerstitial disease secondary to primary Sjogren's disease.
    Li J; Yu YF; Liu CH; Wang CM
    Ren Fail; 2018 Nov; 40(1):634-639. PubMed ID: 30396309
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [A Case of Late Onset Nivolumab-Induced Interstitial Nephritis in a Patient with Metastatic Renal Cell Carcinoma].
    Hattahara K; Yamasaki T; Sawada A; Tanigaki K; Endo S; Teramoto Y; Banno H; Fuchigami Y; Suzuki R; Fujiwara M; Hida T; Yoshino T; Kita Y; Goto T; Akamatsu S; Saito R; Kobayashi T; Inoue T; Ogawa O
    Hinyokika Kiyo; 2019 May; 65(5):157-161. PubMed ID: 31247693
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tubulointerstitial nephritis as adverse effect of programmed cell death 1 inhibitor, nivolumab, showed distinct histological findings.
    Uchida A; Watanabe M; Nawata A; Ikari Y; Sasaki M; Shigemoto K; Hisano S; Nakashima H
    CEN Case Rep; 2017 Nov; 6(2):169-174. PubMed ID: 28849361
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Renal Vasculitis and Pauci-immune Glomerulonephritis Associated With Immune Checkpoint Inhibitors.
    Gallan AJ; Alexander E; Reid P; Kutuby F; Chang A; Henriksen KJ
    Am J Kidney Dis; 2019 Dec; 74(6):853-856. PubMed ID: 31204194
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Variable Expression of Programmed Cell Death Protein 1-Ligand 1 in Kidneys Independent of Immune Checkpoint Inhibition.
    Hakroush S; Kopp SB; Tampe D; Gersmann AK; Korsten P; Zeisberg M; Tampe B
    Front Immunol; 2020; 11():624547. PubMed ID: 33552089
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.